October 17th 2024
Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.
September 23rd 2024
September 18th 2024
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
Rituximab as First-Line Treatment of Patients With Follicular
March 1st 2000There is no standard treatment of stage III-IV follicular lymphoma patients with a low-tumor burden. Rituximab (Rituxan), a chimeric anti-CD20 antibody, is active in pretreated patients with an overall response (OR) rate of 50% and good tolerance.
Commentary (Bierman): High-Dose Therapy for Follicular Lymphoma
March 1st 2000Randomized trials are defining the role of autologous stem-cell transplantation in aggressive non-Hodgkin’s lymphoma (NHL), but there is less experience with this treatment in follicular lymphomas. Approximately 40% to 50% of patients with follicular NHL are in remission 4 to 5 years following autologous stem-cell transplantation. Results from phase II studies and retrospective analyses are remarkably similar, despite differences in patient populations, preparative regimens, use of purging, and source of stem cells. Nevertheless, there is little evidence of a plateau in disease-free survival curves, and we do not know whether patients are cured or overall survival is prolonged. Relapses 9 years following transplantation have been described.[1]
We previously reported that “in vivo purging” with rituximab (Rituxan) during stem-cell collection is safe and does not adversely affect engraftment. We now report on our transplant experience with rituximab. From June 1998 to December
STI 571 Effective Against Some CML/ALL
February 1st 2000PORTLAND, Oregon-A rationally designed drug now known as STI 571 is both effective and well tolerated in treating certain leukemia patients that have not responded to other therapies. The results of two phase I clinical trials using STI 571 for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) were reported by Brian Druker, MD, of the Oregon Health Sciences University in Portland, at the ASH meeting. The trials were conducted in collaboration with M.D. Anderson Cancer Center in Houston, Novartis Pharmaceuticals in East Hanover, New Jersey, and the University of California at Los Angeles.
Choosing AML Consolidation Therapy After Remission
February 1st 2000NEW YORK-Acute myelogenous leukemia (AML) is an aggressive disease. But improved diagnosis with cytogenetic examinations and other special studies have made it possible to select the most effective induction therapy, Frederick R. Appelbaum, MD, told patients at a teleconference sponsored by Cancer Care Inc. and the Leukemia Society of America.
Tositumomab Effective for Untreated and Relapsed, Low-Grade and Follicular NHL
February 1st 2000NEW ORLEANS-The monoclonal antibody tositumomab (Bexxar) showed promising efficacy in low-grade and follicular non-Hodgkin’s lymphoma in several preliminary studies reported during poster presentations at the ASH meeting.
Cladribine Can Produce Response Rate of 80% and Higher in Mantle Cell Lymphomas
February 1st 2000NEW ORLEANS-2-Chlorodeoxyadenosine (cladribine, 2-CdA [Leustatin]) can produce response rates of 80% and higher in patients with mantle cell lymphoma (MCL), according to two studies presented at the ASH meeting. One study examined 2-CdA as monotherapy, and the other studied it combined with mitoxantrone (Novantrone).
Rituximab/CHOP Yields High Initial Response in Mantle Cell Lymphoma
February 1st 2000BOSTON-Adding rituximab (Rituxan) to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) induction therapy may provide a cleaner source of autologous stem cells for use following high-dose therapy in mantle cell lymphoma, Orion Howard, MD, reported at the ASH meeting.
Specific Tyrosine Kinase Inhibitor Highly Active in CML
January 1st 2000NEW ORLEANS-STI 571, an investigational drug for the treatment of chronic myelogenous leukemia (CML), produced complete hematologic responses in all patients receiving higher doses, according to preliminary analysis of phase I data presented at the 41st Annual Meeting of the American Society of Hematology (ASH) (see illustration ). All participants had failed interferon-alfa therapy.
High-Dose Therapy With Stem-Cell Transplantation in the Malignant Lymphomas
December 1st 1999High-dose therapy with hematopoietic progenitor-cell transplantation plays a key role in the treatment of Hodgkin’s disease and the non-Hodgkin’s lymphomas. First and foremost, transplantation is used as a salvage treatment for those who relapse or do not achieve a complete remission with first-line chemotherapy. Carefully selected patients with poor prognostic features may benefit from the incorporation of high-dose therapy and transplant into their initial treatment programs. Despite a myriad of trials, many pivotal questions regarding the appropriate application of high-dose therapy with transplantation to the lymphoid malignancies remain unsettled, including the role of allogeneic transplantation and the optimal timing of transplant for patients with poor prognostic indicators. Phase III studies are required to address these issues; these trials will demand the active commitment of concerned transplanters and referring hematologists and oncologists. Although autologous transplantation has been the preferred approach for the majority of patient subgroups, new approaches to allogeneic transplantation that have diminished toxicity may pave the way for a greater role for allogeneic grafting in the lymphoid diseases. [ONCOLOGY 13(12):1635-1645, 1999]
A New Gold Standard in Advanced Hodgkin’s Disease?
August 1st 1999LUGANO, Switzerland-Dose-escalated BEACOPP chemotherapy (bleomycin, etoposide, Adriamycin [doxorubicin], cyclophosphamide, Oncovin [vincristine], procarbazine, and prednisone) with growth factor support boosts survival in patients with advanced Hodgkin’s disease, according to the fourth interim analysis of the German Hodgkin’s Lymphoma Study Group’s (GHSG) HD9 trial.
Novel Cellular Agent Shows Promise in Treating AML
June 1st 1999Data published in a recent issue of Blood suggest that valspodar (Amdray), a multidrug resistance modulator being developed by Novartis Pharmaceuticals Corporation, may show promise in treating certain patients with acute myelogenous leukemia
Allogeneic BMT Effective in Ph+ Acute Lymphoblastic Leukemia
March 1st 1999MIAMI BEACH-Long-term follow-up of 23 patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission showed a relatively low relapse rate at 3 years when treated with allogeneic bone marrow transplant from HLA-matched siblings, D.S. Snyder, MD, reported at the American Society of Hematology (ASH) annual meeting.
This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with
H pylori Cure Brings Durable CRs in Gastric MALT Lymphoma
March 1st 1999MIAMI BEACH-Chronic inflammation due to Helicobacter pylori infection is the “underlying disease” that causes some gastric lymphomas, and curing the infection produces durable remissions of the neoplasms, Andreas Neubauer, MD, said at the American Society of Hematology (ASH) annual meeting.
Longer Survival Observed With CHVP Plus Interferon in Elderly High-Risk Follicular Lymphoma Patients
February 1st 1999LYON, France-The addition of interferon-alfa-2b (IFN, Intron A) to the usual CHVP regimen (cyclophosphamide, doxorubicin, teniposide, prednisone) extends survival in elderly patients with high-risk follicular lymphoma, Dr. Bertrand Coiffier said at the ASH meeting.
Studies Explore Roles of Chemotherapy and Radiotherapy in Hodgkin’s Disease
February 1st 1999MIAMI BEACH-Hodgkin’s disease (HD) was the focus of an education session and major new research reports at the American Society of Hematology annual meeting. Among the conclusions: Neoadjuvant chemotherapy before radiotherapy provides better outcomes in early-stage HD; moderate dose escalation offers some advantages in advanced disease; and chemotherapy is equal to radiotherapy as consolidation treatment in advanced disease.